GSK plc (NYSE:GSK) Shares Purchased by San Luis Wealth Advisors LLC

San Luis Wealth Advisors LLC raised its stake in GSK plc (NYSE:GSK) by 37.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,968 shares of the pharmaceutical company’s stock after acquiring an additional 6,031 shares during the period. San Luis Wealth Advisors LLC’s holdings in GSK were worth $743,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in GSK. Sunbelt Securities Inc. boosted its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares during the period. EverSource Wealth Advisors LLC lifted its stake in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 303 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its holdings in shares of GSK by 2.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock valued at $682,000 after acquiring an additional 323 shares during the period. Rehmann Capital Advisory Group grew its position in shares of GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares during the last quarter. Finally, Investment Partners Asset Management Inc. increased its holdings in shares of GSK by 2.3% in the 3rd quarter. Investment Partners Asset Management Inc. now owns 15,559 shares of the pharmaceutical company’s stock worth $636,000 after acquiring an additional 344 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Price Performance

NYSE GSK opened at $32.12 on Wednesday. The firm has a market capitalization of $66.57 billion, a PE ratio of 20.86, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company’s 50 day simple moving average is $34.20 and its 200 day simple moving average is $38.08.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.89%. GSK’s dividend payout ratio (DPR) is 95.45%.

Analyst Ratings Changes

GSK has been the subject of a number of analyst reports. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.